Liberostin (Cytisinicline)

Cytisinicline binds selectively to α4β2 nicotinic acetylcholine receptors in the brain, acting as a partial agonist. This produces a modest dopamine release that eases withdrawal while simultaneously blocking nicotine from fully activating the receptor, thereby diminishing the reinforcing effects of smoking.

The specific dose and dosing schedule of Liberostin are determined by the prescribing clinician based on individual patient factors such as smoking history, comorbidities, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Cytisinicline in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing Liberostin to pregnant or nursing individuals, and alternative cessation strategies may be considered.

To request Liberostin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Liberostin’s active ingredient, Cytisinicline, is a partial agonist at nicotinic receptors, similar to varenicline but with a distinct binding profile that may result in different tolerability. Compared with nicotine replacement therapy, it directly targets receptor activity, potentially offering a more focused reduction of cravings.

Liberostin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Liberostin is taken orally as directed by a healthcare professional. The tablet (or other oral form) is swallowed with water, typically at regular intervals defined by the prescriber, and should be used as part of a comprehensive smoking‑cessation program.

Serious adverse events, although rare, can include mood alterations such as depression or suicidal thoughts, cardiovascular complications like hypertension or arrhythmia, severe allergic reactions (anaphylaxis), and, in uncommon cases, seizures. Patients should seek immediate medical attention if these symptoms occur.

Liberostin is contraindicated in individuals with known hypersensitivity to Cytisinicline or any excipients, those with uncontrolled hypertension, and patients currently taking monoamine oxidase inhibitors. It should also be used with caution in patients with significant psychiatric or hepatic conditions, as determined by a healthcare professional.